Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms

MLA

Andreas Sonyi, et al. “Abstract 4549: Pemetrexed Enhances Anti-Tumor Efficacy of PD1 Pathway Blockade by Promoting Intra Tumor Immune Response via Immunogenic Tumor Cell Death and T Cell Intrinsic Mechanisms.” Cancer Research, vol. 78, July 2018, p. 4549. EBSCOhost, https://doi.org/10.1158/1538-7445.am2018-4549.

APA

Andreas Sonyi, Gregory P. Donoho, Jason Manro, Yanxia Li, Sandaruwan Geeganage, Catalina Meyer, David Schaer, Gerald Hall, Ruslan D. Novosiadly, Nelusha Amaladas, Michael Kalos, Carmine Carpenito, Andrew Capen, Zhao Hai Lu, Erik Rasmussen, Thompson N. Doman, Xiaodong Huang, & Shuang Luo. (2018). Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms. Cancer Research, 78, 4549. https://doi.org/10.1158/1538-7445.am2018-4549

Chicago

Andreas Sonyi, Gregory P. Donoho, Jason Manro, Yanxia Li, Sandaruwan Geeganage, Catalina Meyer, David Schaer, et al. 2018. “Abstract 4549: Pemetrexed Enhances Anti-Tumor Efficacy of PD1 Pathway Blockade by Promoting Intra Tumor Immune Response via Immunogenic Tumor Cell Death and T Cell Intrinsic Mechanisms.” Cancer Research 78 (July): 4549. doi:10.1158/1538-7445.am2018-4549.